Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-23.45 M USD-16.53 M USD-7.45 M USD-14.97 M USD-14.50 M USD-13.55 M USD-9.86 M USD-10.77 M USD-12.33 M USD-10.77 M USD-9.60 M USD-9.03 M USD
Depreciation & Amortization0 USD93416 USD103168 USD97915 USD110371 USD67981 USD25000 USD23269 USD566262 USD
Stock-Based Compensation1.45 M USD1.41 M USD407632 USD928052 USD897260 USD736119 USD515762 USD1.22 M USD1.24 M USD1.39 M USD2.10 M USD1.61 M USD
Capital Expenditures447823 USD2331 USD28227 USD50911 USD
Cash Flow from Investing18.10 M USD-28.66 M USD0 USD-12.24 M USD4000 USD0 USD-447823 USD8.50 M USD-278227 USD-50911 USD
Cash Flow from Financing4.59 M USD46.40 M USD11.15 M USD5000 USD33.30 M USD17.89 M USD16.04 M USD9.87 M USD20.12 M USD1.83 M USD2.39 M USD30.71 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-12.78 M USD-10.77 M USD-9.63 M USD-9.08 M USD

CervoMed Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. With a commitment to improving patient outcomes, the company engages in the research and development of innovative therapies that target underlying neurological conditions such as Alzheimer's disease and Parkinson's disease. CervoMed Inc. is recognized for its scientific expertise in neurotherapeutics, exploring promising pathways that could lead to breakthrough solutions. Operating within the highly specialized biotech sector, the company contributes to expanding our understanding of neurobiology and developing targeted interventions. By collaborating with academic institutions, healthcare providers, and industry partners, CervoMed Inc. plays a critical role in advancing medical research and offering hope for patients suffering from debilitating neurological disorders.